Bingteng Xie

Dr. Bingteng Xie

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
BXBingteng Xie
Bingteng Xie
MZMengdi Zhang
Mengdi Zhang
JLJie Li
Jie Li
JCJianxin Cui
Jianxin Cui
PZPengju Zhang
Pengju Zhang
YPYang Pu
Yang Pu
Aberrant lysine lactylation (Kla) is associated with various diseases which are caused by excessive glycolysis metabolism. However, the regulatory molecules and downstream protein targets of Kla remain largely unclear. Here, we observed a global Kla abundance profile in colorectal cancer (CRC) that negatively correlates with prognosis. Among lactylated proteins detected in CRC, lactylation of eEF1A2K408 resulted in boosted translation elongation and enhanced protein synthesis which contributed to tumorigenesis. By screening eEF1A2 interacting proteins, we identified that KAT8, a lysine acetyltransferase that acted as a pan-Kla writer, was responsible for installing Kla on many protein substrates involving in diverse biological processes. Deletion of KAT8 inhibited CRC tumor growth, especially in a high-lactic tumor microenvironment. Therefore, the KAT8-eEF1A2 Kla axis is utilized to meet increased translational requirements for oncogenic adaptation. As a lactyltransferase, KAT8 may represent a potential therapeutic target for CRC.

10 April 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
XLXinyu Ling
Xinyu Ling
BXBingteng Xie
Bingteng Xie
XGXiaoqin Gao
Xiaoqin Gao
LCLiying Chang
Liying Chang
WZWei Zheng
Wei Zheng
TLTao Liu
Tao Liu
A chemical protein-DNA conjugation approach enhances precise genome editing in human cells and mouse zygotes.

27 March 2014 in Protein & Cell
Verified
Journal Article
Open access
PDF file
Qi GuQi Gu
Qi Gu
JHJie Hao
Jie Hao
THTang Hai
Tang Hai
JWJianyu Wang
Jianyu Wang
YJYundan Jia
Yundan Jia
QZQi Zhou
Qi Zhou

6 December 2025 in Journal of Analysis and Testing
Verified
Journal Article
Closed access
PDF file
HCHewen Chen
Hewen Chen
ZZZiyu Zhu
Ziyu Zhu
TLTianjian Lv
Tianjian Lv
QYQian Yang
Qian Yang
SNShan Nan
Shan Nan
ALAxin Liang
Axin Liang

27 May 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
BXBingteng Xie
Bingteng Xie
YPYang Pu
Yang Pu
FYFan Yang
Fan Yang
WCWei Chen
Wei Chen
WYWei Yue
Wei Yue
MLMo Li
Mo Li
Recent work has made it clear that pericentriolar material (PCM), the matrix of proteins surrounding centrioles, contributes to most functions of centrosomes. Given the occurrence of centrosome amplification in most solid tumors and the unconventional survival of these tumor cells, it is tempting to hypothesize that gel-like mitotic PCM would cluster extra centrosomes to defend against mitotic errors and increase tumor cell survival. However, because PCM lacks an encompassing membrane, is highly dynamic, and is physically connected to centrioles, few methods can decode the components of this microscale matrix. In this study, we took advantage of differential labeling between two sets of APEX2-centrosome reactions to design a strategy for acquiring the PCM proteome in living undisturbed cells without synchronization treatment, which identified 392 PCM proteins. Localization of ubiquitination promotion proteins away from PCM was a predominant mechanism to maintain the large size of PCM for centrosome clustering during mitosis in cancer cells. Depletion of PCM gene kinesin family member 20A (KIF20A) caused centrosome clustering failure and apoptosis in cancer cells in vitro and in vivo. Thus, our study suggests a strategy for targeting a wide range of tumors exhibiting centrosome amplification and provides a proteomic resource for future mining of PCM proteins. Significance: This study identifies the proteome of pericentriolar material and reveals therapeutic vulnerabilities in tumors bearing centrosome amplification.

Verified
Journal Article
Open access
PDF file
ZLZiyuan Li
Ziyuan Li
ALAiqin Luo
Aiqin Luo
BXBingteng Xie
Bingteng Xie
ADP-ribosylation is a post-translational modification of proteins that plays a key role in various cellular processes, including DNA repair. Recently, significant progress has been made in understanding the mechanism and function of ADP-ribosylation in DNA repair. ADP-ribosylation can regulate the recruitment and activity of DNA repair proteins by facilitating protein–protein interactions and regulating protein conformations. Moreover, ADP-ribosylation can influence additional post-translational modifications (PTMs) of proteins involved in DNA repair, such as ubiquitination, methylation, acetylation, phosphorylation, and SUMOylation. The interaction between ADP-ribosylation and these additional PTMs can fine-tune the activity of DNA repair proteins and ensure the proper execution of the DNA repair process. In addition, PARP inhibitors have been developed as a promising cancer therapeutic strategy by exploiting the dependence of certain cancer types on the PARP-mediated DNA repair pathway. In this paper, we review the progress of ADP-ribosylation in DNA repair, discuss the crosstalk of ADP-ribosylation with additional PTMs in DNA repair, and summarize the progress of PARP inhibitors in cancer therapy.